Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07207395 · ClinicalTrials.gov registry record · Phase 2
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
A Phase 2 study of Lung Cancer (NSCLC), sponsored by The Christ Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07207395: Recruiting Phase 2 study of Lung Cancer (NSCLC), sponsored by The Christ Hospital.
NCT07207395 is a Phase 2 study of Lung Cancer (NSCLC) that is actively recruiting participants, run by The Christ Hospital. The registered enrollment target is 30 participants, below the 211-participant average among 7 other Lung Cancer (NSCLC) trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07207395, a Phase 2 study of Lung Cancer (NSCLC), is actively recruiting participants, sponsored by The Christ Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.
Primary Outcome
Characterized overall and by type, seriousness, relationship to study treatment, timing, and severity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG JBI-802
Study Locations (1)
Ohio
- The Christ Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What NCT07207395 shows while recruiting
NCT07207395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 211-participant average among 7 other Lung Cancer (NSCLC) trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07207395 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07207395 about?
NCT07207395 is a clinical study titled "A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.". The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.
What is the current status of trial NCT07207395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-04-29. Estimated completion is 2028-10.
What conditions does trial NCT07207395 study?
This clinical trial studies the following conditions: Lung Cancer (NSCLC).
What interventions are being tested in trial NCT07207395?
The interventions under investigation include: Pembrolizumab (DRUG), JBI-802 (DRUG).
Who is sponsoring clinical trial NCT07207395?
This trial is sponsored by The Christ Hospital, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07207395 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
RECRUITING · NA
-
A Study of PHN-012 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI